Guerbet S.A. (GUERF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Guerbet S.A. (GUERF) trades at $22.25 with AI Score 43/100 (Grade C). Guerbet S. A. develops and markets contrast media, delivery systems, and medical devices. Market cap: $281.03M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for GUERF: GUERF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GUERF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GUERF: the 1 perspectives are evenly split.
How is this calculated? →Guerbet S.A. (GUERF) Healthcare & Pipeline Overview
Guerbet S.A., founded in 1926, is a global leader in contrast agents and medical solutions for diagnostic and interventional imaging. The company offers a comprehensive portfolio of products and services for MRI, CT, and interventional radiology, with a focus on innovation and patient safety in the healthcare sector.
What Is the Investment Thesis for GUERF?
Guerbet S.A. presents a mixed investment case. Its established position in the contrast media market and diversified product portfolio provide a stable revenue base. The company's focus on digital solutions and interventional radiology offers growth opportunities. However, the negative profit margin of -14.2% and a P/E ratio of -0.95 raise concerns about profitability. The company's beta of 0.69 suggests lower volatility compared to the market. Upcoming catalysts include potential regulatory approvals for new products and expansion into emerging markets. Investors should monitor the company's ability to improve profitability and manage its debt levels.
Based on FMP financials and quantitative analysis
GUERF Key Highlights
- Market capitalization of $281.03M indicates a relatively small-cap company.
- Negative P/E ratio of -0.95 reflects current losses, requiring careful monitoring of profitability trends.
- Gross margin of 2.4% is significantly lower than industry averages, suggesting potential cost management issues.
- Beta of 0.69 indicates lower volatility compared to the overall market, potentially offering stability during market downturns.
- Dividend yield of 0% indicates that the company does not currently distribute profits to shareholders.
Who Are GUERF's Competitors?
GUERF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BTMD biote Corp. | $2.25 | +3.92% | $99.46M | 74 |
| CSSPF NIOX Group Plc | $0.75 | +0.00% | $315.65M | 47 |
| DLHTF Dialogue Health Technologies Inc. | $3.79 | +0.59% | $254.80M | 56 |
| HTLZF Hamilton Thorne Ltd. | $1.59 | +0.00% | $245.15M | 53 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GUERF's Key Strengths?
- Established presence in the contrast media market.
- Diversified product portfolio across imaging modalities.
- Focus on innovation and digital solutions.
- Global presence with operations in key markets.
What Are GUERF's Weaknesses?
- Negative profit margin and low gross margin.
- High debt levels.
- Dependence on regulatory approvals for new products.
- Limited market share compared to larger competitors.
What Could Drive GUERF Stock Higher?
- Potential regulatory approvals for new contrast agents.
- Expansion into emerging markets in Asia and Latin America.
- Increasing demand for diagnostic imaging procedures.
- Development of new digital solutions for healthcare providers.
What Are the Key Risks for GUERF?
- Negative return on equity (-33.7%) — the business is not currently generating profit on shareholder capital.
- Intense competition from larger players in the contrast media market.
- Pricing pressures and reimbursement challenges.
- Regulatory changes and compliance requirements.
- Product liability risks associated with medical devices.
- Negative profit margin and low gross margin.
What Are the Growth Opportunities for GUERF?
- Expansion of Digital Solutions: Guerbet's digital solutions, such as Contrast&Care and Dose&Care, offer significant growth potential. The market for digital healthcare solutions is expanding rapidly, driven by the need for improved efficiency and patient outcomes. By leveraging its expertise in contrast media and imaging, Guerbet can develop innovative digital tools that integrate seamlessly with existing workflows. The global market for healthcare IT solutions is projected to reach $390 billion by 2027, providing a substantial opportunity for Guerbet to increase its market share.
- Growth in Interventional Radiology: Guerbet's interventional radiology products, including Lipiodol and Vectorio, target a growing market driven by minimally invasive procedures. The increasing prevalence of liver cancer and other chronic diseases is driving demand for TACE and other interventional treatments. Guerbet's focus on innovative delivery systems and specialized products positions it well to capitalize on this trend. The interventional radiology market is expected to reach $35 billion by 2028, offering a significant growth opportunity for Guerbet.
- Geographic Expansion in Emerging Markets: Guerbet has the opportunity to expand its presence in emerging markets, where demand for diagnostic imaging is growing rapidly. These markets offer significant potential for increased sales of contrast media and related products. By establishing strategic partnerships and tailoring its product offerings to local needs, Guerbet can gain a foothold in these markets and drive long-term growth. The emerging markets healthcare sector is projected to grow at a rate of 8-10% annually over the next five years.
- New Product Development and Innovation: Guerbet can drive growth through continuous innovation and the development of new contrast agents and delivery systems. By investing in research and development, the company can introduce novel products that address unmet clinical needs and improve patient outcomes. This includes developing contrast agents with improved safety profiles and enhanced imaging capabilities. The pharmaceutical and medical device industries rely heavily on innovation, and Guerbet's commitment to R&D is crucial for maintaining its competitive edge.
- Strategic Partnerships and Acquisitions: Guerbet can pursue strategic partnerships and acquisitions to expand its product portfolio and geographic reach. By collaborating with other companies in the medical imaging field, Guerbet can gain access to new technologies and markets. Acquisitions can also provide opportunities to consolidate the market and increase market share. The healthcare industry is characterized by frequent mergers and acquisitions, and Guerbet can leverage these opportunities to accelerate its growth.
What Opportunities Does GUERF Have?
- Expansion in emerging markets.
- Growth in interventional radiology.
- Development of new contrast agents and delivery systems.
- Strategic partnerships and acquisitions.
What Threats Does GUERF Face?
- Intense competition from larger players.
- Pricing pressures and reimbursement challenges.
- Regulatory changes and compliance requirements.
- Product liability risks.
What Are GUERF's Competitive Advantages?
- Established brand reputation in the contrast media market.
- Specialized expertise in contrast agent development and delivery systems.
- Proprietary technologies and intellectual property.
- Strong relationships with healthcare providers.
What Does GUERF Do?
Founded in 1926 and headquartered in Villepinte, France, Guerbet S.A. has evolved into a key player in the medical imaging field. The company specializes in developing and marketing contrast media, delivery systems, medical devices, and related solutions. Guerbet's initial focus was on the development of Lipiodol, an iodinated poppyseed oil used in radiology. Over the decades, Guerbet expanded its product portfolio to include a range of contrast agents for various imaging modalities, including MRI, CT, and X-ray. Key products include Optiray and Xenetix, non-ionic iodinated contrast agents used in CT scans, and Dotarem, a gadolinium-based contrast agent for MRI. The company also offers digital solutions like Contrast&Care and Dose&Care to improve injection management and dose optimization. Guerbet's interventional radiology products include Lipiodol and Vectorio, used in trans-arterial chemoembolization (TACE) for liver cancer treatment. Guerbet operates globally, with a presence in Europe, the Americas, and Asia. The company competes with major players in the contrast media market, focusing on innovation and strategic partnerships to maintain its market position.
What Products and Services Does GUERF Offer?
- Develops and markets contrast media products for medical imaging.
- Offers delivery systems for contrast agents used in MRI, CT, and X-ray.
- Provides medical devices and related solutions for diagnostic and interventional imaging.
- Offers contrast agents like Optiray and Xenetix for CT scans.
- Provides Dotarem, a gadolinium-based contrast agent for MRI.
- Offers digital solutions like Contrast&Care and Dose&Care for injection management and dose optimization.
- Provides products for interventional radiology, including Lipiodol and Vectorio.
How Does GUERF Make Money?
- Develops and manufactures contrast media products.
- Sells contrast media and delivery systems to hospitals and imaging centers.
- Offers digital solutions and services to healthcare providers.
- Generates revenue through product sales and service contracts.
What Industry Does GUERF Operate In?
Guerbet S.A. operates in the medical instruments and supplies industry, which is characterized by technological innovation, stringent regulatory requirements, and increasing demand for advanced imaging solutions. The global contrast media market is expected to grow, driven by the rising prevalence of chronic diseases and the increasing adoption of diagnostic imaging procedures. Guerbet competes with larger players in the market, such as BTMD, CSSPF, DLHTF, HTLZF, and NWPHF, focusing on niche markets and specialized products to differentiate itself.
Who Are GUERF's Key Customers?
- Hospitals and clinics
- Radiology and imaging centers
- Interventional radiology specialists
- Healthcare professionals
F-Score 8/9Financial Health
Guerbet S.A.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.54 places it in the grey zone, a middle ground that warrants monitoring.
ROE -34%Key Financial Metrics
Return on equity for Guerbet S.A. stands at -33.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 28.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.49 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -96.1%, the inverse of the P/E and a quick read on earnings relative to price.
GUERF Valuation & Market Position
With a $281.03M market cap, Guerbet S.A. sits in the micro-cap segment of the market. Relative to its peer group, GUERF's quantitative score of 43/100 is below the peer average of 60/100.
GUERF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Guerbet's future performance, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product launches that could enhance market share.
- Analysts are noting improvements in operational efficiency, which could lead to better profit margins and overall financial health.
- Guerbet's strategic partnerships in the healthcare sector are gaining traction, reinforcing its position as a key player in medical imaging.
Bear Case
- Concerns about regulatory changes in the healthcare industry have surfaced, which could impact Guerbet's operational landscape.
- Recent social sentiment reflects skepticism regarding the scalability of new technologies, raising questions about long-term growth prospects.
- The competitive landscape in medical imaging is intensifying, with several companies launching similar products, potentially eroding Guerbet's market advantage.
- Some community voices are highlighting the company's reliance on a few key products, which poses risks if those products underperform.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GUERF Latest News
No recent news available for GUERF.
GUERF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GUERF.
Price Targets
Wall Street price target analysis for GUERF.
GUERF MoonshotScore
What does this score mean?
The MoonshotScore rates GUERF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Hale
CEO
David Hale serves as the CEO of Guerbet S.A. His background includes extensive experience in the healthcare industry, with a focus on medical devices and imaging solutions. He has held leadership positions in various multinational companies, driving growth and innovation. Hale's expertise spans strategic planning, product development, and market expansion. His educational background includes advanced degrees in business and engineering.
Track Record: Under David Hale's leadership, Guerbet S.A. has focused on expanding its digital solutions and interventional radiology offerings. Key milestones include the launch of new contrast agents and the implementation of strategic partnerships to strengthen the company's market position. Hale has emphasized innovation and operational efficiency to improve profitability and drive long-term growth.
GUERF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Guerbet S.A. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Lack of regulatory oversight
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any legal or regulatory issues.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Established history of operations since 1926.
- Presence in the medical imaging market.
- Global operations with a presence in multiple countries.
- Development of contrast media and related solutions.
Guerbet S.A. Healthcare Stock: Key Questions Answered
What does Guerbet S.A. do?
Guerbet S.A. specializes in developing and marketing contrast media, delivery systems, medical devices, and related solutions for diagnostic and interventional imaging. The company's products are used in MRI, CT, and X-ray procedures to enhance the visibility of internal organs and tissues. Guerbet's offerings include contrast agents, injectors, and digital solutions designed to improve patient outcomes and streamline workflows for healthcare providers. The company operates globally, serving hospitals, clinics, and imaging centers.
What do analysts say about GUERF stock?
Analyst coverage of GUERF stock is limited due to its OTC listing. Key valuation metrics, such as the negative P/E ratio, reflect current losses. Growth considerations include the company's expansion into digital solutions and emerging markets. Investors should carefully monitor the company's financial performance and competitive landscape. There is no consensus rating available due to the limited coverage.
What are the main risks for GUERF?
The main risks for GUERF include intense competition from larger players in the contrast media market, pricing pressures and reimbursement challenges, regulatory changes and compliance requirements, and product liability risks associated with medical devices. The company's negative profit margin and low gross margin also pose significant financial risks. Additionally, the OTC listing introduces risks related to liquidity, transparency, and regulatory oversight.
What revenue streams does Guerbet S.A. have in healthcare?
Guerbet S.A.'s revenue streams are primarily derived from the sale of contrast media products across various imaging modalities, including MRI, CT, and X-ray. Additional revenue is generated from the sale of delivery systems, medical devices, and digital solutions. The company's revenue is also segmented by geographic market, with a significant portion coming from Europe, the Americas, and Asia. The specific breakdown of revenue by product line, therapeutic area, and geographic market is not publicly available.
How does Guerbet S.A. manage its supply chain?
Guerbet S.A. manages its supply chain by sourcing raw materials and components from various suppliers globally. The company has established quality control processes to ensure the safety and efficacy of its products. Guerbet also works closely with its suppliers to optimize costs and minimize disruptions. The company's supply chain is subject to regulatory requirements and compliance standards, which are closely monitored to ensure adherence.
What are the key factors to evaluate for GUERF?
Guerbet S.A. (GUERF) holds an AI score of 43/100 (low). Not financial advice.
How frequently does GUERF data refresh on this page?
GUERF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GUERF's recent stock price performance?
Guerbet S.A. (GUERF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the contrast media market. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to the OTC listing.
- Analyst coverage is sparse, making it difficult to assess market sentiment.